Europe
A report about Amsterdam-based uniQure indicated it is looking at various options, including a potential sale. As a result, company stock jumped as much as 10% in premarket trading.
Researchers with The Institute of Cancer Research, London, used a modified version of the virus used in the smallpox vaccine—vaccinia—to stimulate the immune system against cancer in laboratory animals with sarcoma.
MorphoSys AG announced that its licensee Janssen Research & Development, LLC, reported top-line results from the phase 3 DISCOVER 1 and 2 studies in a press release issued.
Data Supporting the Potential of Voxelotor as a Disease-Modifying Treatment for Sickle Cell Disease (SCD) Published in The New England Journal of Medicineandto bePresented During Presidential Symposium at the 24thEuropean Hematology Association (EHA) Congress
GENFIT announced the results of the voting by shareholders at the Ordinary Shareholders’ Meeting which took place on June 13, 2019, in Lille, France.
Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look.
Tremfya hit the mark in two late-stage psoriatic arthritis trials, setting the stage for another potential approval.
Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful skin ulcers
A substantial number of blood cancer patients could make more informed decisions on their treatment if more information becomes available for them and their treating physicians.
Lifestyle-related diseases, an ageing population and rapid technical progress all mean that major investments need to be made in the life science sector over the next few years. Semcon is now increasing the pace of its growth in this field.
PRESS RELEASES